ArticleCurrent issues in molecular biology2026
Design, Synthesis, and Proof-of-Concept Bioassay of an Encapsulated mRNA for Human Growth Hormone.
Article in Current issues in molecular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundHuman growth hormone (hGH) deficiency (GHD) is typically treated with daily injections of recombinant human growth hormone (rhGH), which do not fully replicate physiological secretion patterns. This study evaluates a novel approach using synthetic mRNA encoding hGH encapsulated in lipid nanoparticles (LNPs) and designated VTRC-01 to enable endogenous hormone production.
methodsVTRC-01 was administered intramuscularly to hypophysectomized (Hypox) prepubertal Wistar rats, and its efficacy was compared with rhGH. A cohort of healthy rats was included to assess anabolic effects and safety.
resultsVTRC-01 stimulated longitudinal growth in both Hypox and healthy rats, achieving effects comparable to rhGH. Treatment induced a significant anabolic response that exceeded the basal growth rate of healthy controls.
conclusionsThese findings provide proof-of-concept for hGH mRNA-based therapy as a promising alternative to rhGH. Further improvements in mRNA and LNP technologies are expected to enhance safe hormone production. These promising results underscore the potential of reprogramming via therapeutic mRNA the synthesis of key endocrine regulators (such as hGH) directly within the organism, offering for the first time a powerful pathway for the potential treatment for endocrine therapies targeting growth hormone deficiency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.